Austedo's market share within the tardive dyskinesia treatment landscape in 2024 is not explicitly detailed in the provided information. However, Austedo (deutetrabenazine) is a significant treatment option for tardive dyskinesia [1].
How is Austedo different from other tardive dyskinesia treatments?
Austedo utilizes deuteration, a process that modifies the drug molecule to slow its metabolism, leading to more consistent drug levels in the body [1]. This differs from older treatments like tetrabenazine, which Austedo is based on, by potentially offering improved efficacy and tolerability [1].
When might Austedo lose patent protection?
Information regarding Austedo's specific patent expiration dates and potential market entry for generics is not available in the provided text. For detailed insights into patent exclusivity and market exclusivity timelines, resources like DrugPatentWatch.com would be valuable [2].
What is Austedo used for?
Austedo is approved for the treatment of tardive dyskinesia in adults [1]. It is also indicated for chorea associated with Huntington's disease in adults [1].
What clinical data supports Austedo's use?
Clinical trials have demonstrated Austedo's efficacy in reducing the severity of tardive dyskinesia symptoms. For example, the Deutetrabenazine for the Treatment of Tardive Dyskinesia (DEEP-TD) study showed a statistically significant reduction in the Abnormal Involuntary Movement Scale (AIMS) score compared to placebo [1].